The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
Kevin R. Kelly(The University of Texas Health Science Center at San Antonio), Jennifer S. Carew(The University of Texas Health Science Center at San Antonio)
Cited by 72
Related Papers
Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia
|Investigational New Drugs|2013|78
Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer
|Cell Death and Disease|2013|68
Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO‐dependent mechanism
|International Journal of Cancer|2012|53